ACADIA Pharma cut at Morgan Stanley on Daybue miss

New York financial district, Wall Street

LeoPatrizi

Despite ACADIA Pharmaceuticals’ (NASDAQ:ACAD) Q2 beat yesterday, Morgan Stanley downgraded the stock on Wednesday, arguing that its recently launched brain disorder therapy Daybue fell short of expectations.

Daybue, indicated in the U.S. for patients aged two years and older with the neurodevelopmental

Leave a Reply

Your email address will not be published. Required fields are marked *